Daniel W. Bowles

Table S6 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation

Rona Yaeger, Meredith McKean, Rizwan Haq, J. Thaddeus Beck et autres

Table S6. Antibodies used for preclinical experiments

Table S4 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation

Rona Yaeger, Meredith McKean, Rizwan Haq, J. Thaddeus Beck et autres

Table S4. Treatment-Emergent Adverse Events (≥3 patients) with PF-07799933 monotherapy and combination therapy

Figure S1 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation

Rona Yaeger, Meredith McKean, Rizwan Haq, J. Thaddeus Beck et autres

Figure S1. Preclinical characterization of PF-07799933 and comparison to other RAF inhibitors.

Table S5 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation

Rona Yaeger, Meredith McKean, Rizwan Haq, J. Thaddeus Beck et autres

Table S5. Preliminary mutation analysis

Figure S3 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation

Rona Yaeger, Meredith McKean, Rizwan Haq, J. Thaddeus Beck et autres

Figure S3. Mouse plasma PK profiles for exarafenib and plixorafenib.

Table S2 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation

Rona Yaeger, Meredith McKean, Rizwan Haq, J. Thaddeus Beck et autres

Table S2. X-ray crystallography data collection and refinement statistics

Table S3 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation

Rona Yaeger, Meredith McKean, Rizwan Haq, J. Thaddeus Beck et autres

Table S3. Demographic and clinical characteristics of the patients

Figure S4 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation

Rona Yaeger, Meredith McKean, Rizwan Haq, J. Thaddeus Beck et autres

Figure S4. Patient PK profiles for PF-07799933.

Table S1 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation

Rona Yaeger, Meredith McKean, Rizwan Haq, J. Thaddeus Beck et autres

Table S1. Cell lines used for cell-based pERK assays in Figure 1A

Figure S2 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation

Rona Yaeger, Meredith McKean, Rizwan Haq, J. Thaddeus Beck et autres

Figure S2. Crystal structures of BRAF kinase domain with PF-07799933 or encorafenib.

Figure S5 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation

Rona Yaeger, Meredith McKean, Rizwan Haq, J. Thaddeus Beck et autres

Figure S5. Efficacy for BRAF non-V600/Class II and Class III-mutant cancer patients.

A phase 2 study of darolutamide plus leuprolide acetate in hormone therapy–naïve recurrent and/or metastatic androgen receptor (AR)–positive salivary gland cancer (ETCTN 10553).

Alan L. Ho, Varinder Kaur, Shetal Patel, Renata Ferrarotto et autres

6012 Background: A subset of salivary gland cancers (SGCs) express the androgen receptor (AR). A prior AR+ SGC trial with the anti-androgen enzalutamide alone failed to meet its primary endpoint. This is a multicenter, phase II study evaluating the efficacy and safety …

us (code pays fourni par la source)